黑龙江珍宝岛药业股份有限公司关于控股股东拟办理非公开发行可交换公司债券股份补充质押的提示性公告

Core Viewpoint - The announcement details the plan of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.'s controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., to supplement the pledge of shares to secure the repayment of bonds and facilitate share exchanges [2][3]. Group 1: Share Pledge Details - As of February 2, 2026, Chuangda Group holds 530,561,726 shares of the company, accounting for 56.38% of the total share capital, with 427,276,426 shares pledged, representing 80.53% of its holdings [2]. - Chuangda Group plans to pledge an additional 1,170,000 shares (0.12% of total share capital, 0.22% of its holdings) to secure the repayment of the second phase of the non-public exchangeable bonds (23 Chuang02EB) [2][3]. - After the completion of this pledge, the total number of pledged shares will increase to 428,446,426, which is 80.75% of Chuangda Group's holdings [3]. Group 2: Financial and Operational Status - Chuangda Group has no controlling persons and has not engaged in any actions that would harm the interests of the listed company, such as non-operational fund occupation or illegal guarantees [7]. - The pledge will not adversely affect the company's main business or operational capabilities, nor will it lead to changes in control [7]. - Chuangda Group's financial health is stable, with no significant litigation or arbitration related to debt issues, and it has sufficient repayment capabilities through operational cash flow and dividends from subsidiaries [11][12].